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Abstract: The purpose of this cross-sectional pilot study was to find salivary microRNAs
(miRNAs) reflecting periodontal condition in chronic periodontitis. One hundred and twenty chronic
periodontitis patients (mean age, 68.4 years) participated in the study, from whom unstimulated
whole saliva was collected. A multiphase study was conducted to explore salivary miRNAs as
biomarkers of periodontitis. At first, a polymerase chain reaction (PCR) array was performed to
compare salivary miRNAs profiles in no and mild (no/mild) and severe periodontitis patients. Next,
the relative expression of salivary miRNAs on individual samples was assessed by real-time reverse
transcription-PCR. The numbers (%) of patients were 26 (21.6%, no/mild), 58 (48.3%, moderate) and
36 (30.0%, severe), respectively. Among 84 miRNAs, only the relative expression of hsa-miR-381-3p
in the severe periodontitis group was significantly higher than that of the no/mild periodontitis
group (p < 0.05). Among the 120 patients, there was also a significant correlation between the relative
expression of hsa-miR-381-3p and the mean probing pocket depth (PPD) (r = 0.181, p < 0.05). Salivary
hsa-miR-381-3p was correlated with periodontitis condition in chronic periodontitis patients.
Keywords: saliva; periodontitis; microRNA
1. Introduction
Periodontitis is a chronic inflammation which causes the destruction of gingival connective
tissue, periodontal ligament, cementum and alveolar bone loss. Periodontitis is classified as no
periodontitis, mild periodontitis, moderate periodontitis or severe periodontitis, according to the
degree of disease progression [1,2]. The risk of tooth loss caused by periodontitis varies according to
disease progression [3]. Therefore, development of examination methods for periodontal condition is
important for estimating the risk of tooth loss.
Traditionally, periodontitis severity is evaluated by measuring probing pocket depth (PPD) and
clinical attachment levels (CAL) [1]. However, measuring PPD and CAL is a technically demanding
process that requires a high degree of skill. In addition, these parameters do not reflect present
periodontitis activity, but simply assess the cumulative effects of periodontal tissue destruction. A new
rational diagnosis of periodontitis condition would have concomitant patient benefits because the
paucity of evidence-based knowledge of disease severity in individual periodontitis patients may lead
to unintentional clinical mismanagement.
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Recent studies have reported that measuring salivary mediators can be useful in determining
periodontal condition [4,5]. For example, cytokines [6], lactate dehydrogenase [7–11], lactoferrin [12–14]
and 8-hydroxydeoxyguanosine [15–17] are known as possible salivary biomarkers for periodontal
condition. Salivary mediators associated with periodontal condition may help in the development of
novel diagnostics for periodontitis.
miRNAs (micro RNAs) are single strained non-coding small RNAs (~22-nucleotide) which
regulate post-transcriptional repression of target messenger RNAs (mRNAs) [18]. MiRNAs exist in
several body fluids, including saliva. Recent studies have shown that periodontitis can modulate
the periodontal tissue levels of miRNAs [19,20], which may also change miRNA profile in
saliva [21]. However, the relationship between salivary miRNAs profile and periodontal condition
remains obscure.
In the present work, we hypothesized that salivary miRNA profiles vary according to the
periodontal condition. Therefore, the aim of this cross-sectional pilot study was to investigate the
relationship between salivary miRNAs and periodontal condition in chronic periodontitis patients.
2. Results
2.1. Characteristics of Patients
One hundred and twenty patients (mean age, 68.4) were recruited in this study and were
classified according to periodontal severity (see Methods). The number of participants of the no/mild
periodontitis group, the moderate periodontitis group, and the severe periodontitis group was 26, 58,
and 36 respectively (Table 1). We evaluated the characteristics of the patients, including age, gender,
number of teeth present, mean PPD, mean CAL, bleeding on probing (BOP) (%), plaque control record
(%), smoking status, presence of diabetes mellitus, and frequency of tooth brushing per day. In terms
of patient characteristics, except age, mean PPD, mean CAL, BOP and number of teeth, significant
differences were not recognized between the groups.
Table 1. Characteristics of the participants (n [%] or mean [SD]).
Variables Categories
Total
(N = 120)
Severity of Periodontitis
No/Mild Moderate Severe
(N = 26) (N = 58) (N = 36) p Value
Age (years) 68.4 (10.2) 63.3 (13.9) 68.6 (8.7) 71.7 (7.9) 0.005 *
Gender Male 38 (31.7) 6 (23.1) 18 (31.0) 14 (38.9) 0.414 †
Number of teeth present 23.6 (5.0) 25.5 (3.7) 24.3 (4.3) 21.0 (6.0) <0.001 *
Mean PPD (mm) 2.0 (0.4) 1.9 (0.2) 2.0 (0.3) 2.3 (0.5) <0.001 *
Mean CAL (mm) 2.8 (1.2) 1.9 (0.2) 2.6 (0.7) 3.9 (1.4) <0.001 *
BOP (%) 7.7 (9.0) 6.9 (9.2) 5.8 (4.9) 11.3 (12.7) 0.015 *
Plaque control record (%) 22.2 (20.3) 18.1 (14.7) 24.0 (20.3) 22.3 (24.0) 0.486 *
Smoking status Current 6 (5.0) 0 (0) 2 (3.4) 4 (11.1) 0.109 †
BMI 22.5 (3.0) 22.0 (2.7) 22.2 (2.7) 23.3 (3.3) 0.162 *
Diabetes mellitus Present 12 (10.0) 2 (7.7) 8 (13.8) 3 (5.6) 0.392 †
Frequency of toothbrushing/day 2.5 (0.7) 2.6 (0.6) 2.3 (0.7) 2.7 (0.8) 0.052 *
* one-way analysis of variance. † Chi-square test. PPD, probing pocket depth; CAL, clinical attachment level; BOP,
bleeding on probing; BMI, body mass index.
2.2. Selection of Candidate miRNAs Reflecting Periodontitis
To screen candidate miRNAs reflecting periodontitis, Inflammatory Response and an Autoimmunity
miScript miRNAs PCR Array (SA Biosciences, Frederick, MD) using pooled sample (no/mild
periodontitis group vs severe periodontitis group, n = 3/group) were conducted. Among 84 miRNAs,
there was only a significant difference in hsa-miR-381-3p between the no/mild periodontitis group and
the severe periodontitis group (p = 0.015). Furthermore, three miRNAs (hsa-miR381-3p, hsa-miR-543,
and hsa-miR-144-3p) were upregulated (fold change > 2) in the severe periodontitis group, as compared
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with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-5p) was down-regulated
(fold change < 0.5) in the severe periodontitis group, as compared with the no/mild periodontitis group.
From these data, hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and hsa-miR-30b-5p were selected for
further analysis.
Table 2. List of the differentially expressed miRNAs between severe and no/mild periodontitis
(Fold Change >2 or < 0.5).
miRNAs
Average Ct Average
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group, as compared with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-
5p) was down-regulated (fold change < 0.5) in the severe periodontitis group, as compared with the 
no/mild periodontitis group. From these data, hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa-miR-30b-5p were selected for further analysis. 
Table 2. List of the differentially expressed miRNAs between severe and no/mild periodontitis (Fold 
Change >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
Fold Change p Value 
No/Mild Severe No/Mild Severe no/Mild Severe 
hsa-miR-381-3p 34.88 33.05 2.3  0.49 0.20 0.71 3.63 0.01 
hsa-miR-543 34.89 33.48 2.36 0.92 0.20 0.53 2.70 0.12 
hsa-miR-144-3p 33.92 32.84 1.39 0.28 0.38 0.82 2.16 0.51 
hsa-miR-30b-5p 30.05 31.32 −2.48 −1.24 5.57 2.36 0.42 0.14 
housekeeping small RNA 32.53 32.56       
Fold-change values greater than one indicate up-regulation and less than one indicate down-regulation. 
Average ⊿Ct = Average Ct (miRNA) − Average ⊿Ct (housekeeping small RNA). Fold change = 2^ 
(- r e⊿Ct (severe))/2^ (-Average⊿Ct (no/mild)). Average Ct values of housekeeping small 
RNAs mean average Ct of SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value 
was calculated by the Student’s t-test. 
2.3. Evaluating Validation of Selected miRNAs 
We selected hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and hsa-miR-30b-5p and performed 
the quantitative real-time PCR assays by inventoried TaqMan miRNA assays (Applied Biosystems, 
Foster City, CA, USA) for all participants (Figure S2). There were no significant differences in miRNAs 
expression among three groups. Next, we evaluated the relationships between the relative 
expressions of the miRNAs and clinical parameters (mean PPD, mean CAL, BOP, and Plaque control 
record) by Pearson’s correlation test. There was a significant positive mild correlation between the 
relative expression of hsa-miR-381-3p and mean PPD (r = 0.181, p = 0.047) (Figure 1). In addition, we 
examined the relationship between hsa-miR-381-3p and mean PPD by the stepwise method of 
multiple linear regression analysis. It was also shown that the relative expression of hsa-miR-381-3p 
was significantly correlated with mean PPD (p = 0.049) (Table 3) by the multiple linear regression 
analysis. For the other miRNAs, there was no significant correlation between the relative expressions 
of the miRNAs and the clinical parameters. 
Table 3. Multiple linear regression analysis with mean PPD as the dependent variable (N = 120). 
Variables B (95%CI) β p Value VIF 
Intercept 1.917 (1.760, 2.073) - <0.001 - 
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1.036 
Gender −0.148 (−0.279, −0.017) −0.187 0.027 1.036 
hsa-miR-381-3p 0.054 (0.010, 0.123) 0.166 0.049 1.022 
The candidate variables for the model were age, gender, BOP (%), Plaque control record (%), number 
of teeth present, and hsa-miR-381-3p. We selected candidate valuables which have significantly 
correlated with mean PPD in Pearson’s correlation analysis (p < 0.05). The final model was constructed 
based on the maximum adjusted R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), 
the R-squared was 0.212, and the adjusted R-squared was 0.191. N: number. CI: confidence interval. 
B: unstandardized regression coefficient. β: standardized coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t Average 2ˆ-
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group, as compar d with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-
5p) was down-regulated (fold change < 0.5) in the severe periodontitis group, as compared with the 
no/mild periodontitis group. From these dat , hsa-miR-381 3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa-miR-30b-5p were selected for further analysis. 
Table 2. List of the differentially expressed miRNAs betwe n severe and no/mild periodontitis (Fold 
Change >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
Fold Change p Value 
No/Mild Severe No/Mild Severe no/Mild Severe 
hsa-miR-381-3p 34.88 33.05 2.35 0.49 0.20 .7  3.63 0.01 
hsa-miR-543 34.89 33.48 2.36 0.92 .20 .53 2.70 0.12 
hsa-miR-144-3p 33.92 32.84 1.39 0.28 0.38 .82 2.16 0.51 
hsa-miR-30b-5p 30.05 31.32 −2.48 −1.24 5.57 2.36 0.42 0.14 
housekeeping small RNA 32.53 32.56       
Fold-cha ge values great r than one indicate up-regulation and less than one indicate down-regulation. 
Average ⊿Ct = era e Ct (miRNA) − Average ⊿Ct (housekeeping small RNA). Fold change = 2^ 
(-Averag ⊿Ct (severe))/2^ (-Average⊿Ct (no/mild)). Averag  Ct values of housekeeping small 
RNAs mean average Ct of SNORD61, SNORD 8, SNO D95, SNORD96A and RNU6-6p. The p value 
was calculated by the Student’s t-test. 
2.3. Eva uating Validation of Selected miRNAs 
We selected hsa miR-381-3p, hsa-miR-543, hsa- iR-144-3p, and hsa-miR-30b-5p and performed 
the quantitative real-time PCR assays by inventoried TaqMan miRNA assay  (Applied Biosystems, 
F ster City, CA, USA) fo  all participants (Figure S2). There were no significant differences in miRNAs 
expression among thr e groups. Next, we evaluated th  relationships between the relative 
expressions of the miRNAs and cli ical parameters (mean PPD, mean CAL, BOP, and Plaque control 
record) by Pearson’s correl tion test. There was a significant positive mild correlation between the 
rel tive expressio  of hs -miR-381-3p and mean PPD (r = 0.181, p = 0.047) (Figure 1). In addition, we 
examin d the relationship between hsa-miR-381-3p and mean PPD by the stepwise method of 
multiple linear regressi n analysis. It was also shown that the rel tive expression of hsa-miR-381-3p 
w s sign ficantly correlated with me n PPD (p = 0.049) (Tab e 3) by th  multiple linear regression 
analysis. For the other m RNAs, there was no significant co relation between the relative expressions 
of the miRNAs and the clinical parameters. 
Table 3. Multiple linear regression analysis with mean PPD as the dependent variable (N = 120). 
Variables B (95%CI) β p Value VIF 
Intercept 1.917 (1.760, 2.073) - <0.001 - 
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1.036 
Gender −0.148 (−0.279, −0. 17) −0.187 0.027 1.036 
hsa-miR-381-3p 0.054 (0.010, 0.123) 0.166 0.049 1.022 
The candidate va iabl s for the model were ge, gender, BOP (%), Plaque control record (%), number 
of teeth present, and hsa-miR-381-3p. We selected candidate valuables which have significantly 
correlated with mean PPD i  Pear on’s correlation analysis (p < 0.05). The final model was constructed 
based on the maximum adjusted R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), 
the R-squ red was 0.212, an  the adjusted R-squared was 0.191. N: number CI: confidence interval. 
B: u standardized regression coefficient. β: standardized coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t
Fold Change p Value
No/Mild Severe No/Mild Severe no/Mild Severe
hsa-miR-381-3p 34.88 33.05 2.35 0.49 0.20 0.71 3.63 0.01
hsa-miR-543 34.89 33.48 2.36 0.92 0.20 0.53 2.70 0.12
hsa-miR-144-3p 33.92 32.84 1.39 0.28 0.38 0.82 2.16 0.51
hsa-miR-30b-5p 30.05 31.32 −2.48 −1.24 5.57 2.36 0.42 0.14
housekeeping small RNA 32.53 32.56
Fold-change values greater than one indicate up-regulation and less than one indicate down-regulation. Average
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group, as compared with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-
5p) was down-r gulated (fold cha ge < 0.5) in the severe p riodontitis group, as compared with the 
no/mild periodontitis group. From th se data, hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa-miR-30b-5p were selected for further analysis. 
Table 2. List of the differentially expressed miRNAs between severe and no/mild periodontitis (Fold 
Change >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
Fold Change p Value 
No/Mild Severe No/Mild Severe no/Mild Severe 
hsa-miR-381-3p 34.88 33.05 2.35 0.49 0.20 0.71 3.63 0.01 
hsa-miR-543 34.89 33.48 2.36 0.92 0.20 0.53 2.70 0.12 
hsa-miR-144-3p 33.92 32.84 1.39 0.28 0.38 0.82 2.16 0.51 
hsa-miR-30b-5p 30.05 31.32 −2.48 −1.24 5.57 2.36 0.42 0.14 
housekeeping small RNA 32.53 32.56       
Fold-change values greater than one indicate up-regulation and less than one indicate down-regulation. 
Average ⊿Ct = Average Ct (miRNA) − Average ⊿Ct (housekeeping sm ll RNA). Fol  change = 2^ 
(-Average⊿Ct (severe))/2^ (-Average⊿Ct (no/mild)). Average Ct values of housekeeping small 
RNAs mean average Ct of SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value 
was calculated by the Student’s t-test. 
2.3. Evaluating Validation of Selected miRNAs 
We selected hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and hsa-miR-30b-5p and performed 
the quantitative real-time PCR assays by inventoried TaqMan miRNA a ays (Appli d Biosy tems, 
Foster City, CA, USA) for all participants (Figure S2). There were o significant differences in miRNAs 
expression among three groups. Next, we evaluated the relationships between the relative 
expressions of the miRNAs and clinical parameters (mean PPD, mean CAL, BOP, and Plaque control 
record) by Pearson’s correlation test. There was a significant positive mild correlation between the 
relative expression of hsa-miR-381-3p and mean PPD (r = 0.181, p = 0.047) (Figure 1). In addition, we 
examined the relationship between hsa-miR-381-3p and mean PPD by the stepwise method of 
multiple linear regression analysis. It was also shown that the relative expression of hsa-miR-381-3p 
was significantly correlated with mean PPD (p = 0.049) (Table 3) by the multipl  lin r regressi n 
analysis. For the other miRNAs, there was no significant correlation between t e relative xpressions 
of the miRNAs and the clinical parameters. 
Table 3. Multiple linear regression analysis with mean PPD as the dependent variable (N = 120). 
Variables B (95%CI) β p Value VIF 
Intercept 1.917 (1.760, 2.073) - <0.001 - 
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1.036 
Gender −0.148 (−0.279, −0.017) −0.187 0.027 1.036 
hsa-miR-381-3p 0.054 (0.010, 0.123) 0.166 0.049 1.022 
The candidate variables for the model were age, gender, BOP (%), Plaque control record (%), number 
of teeth present, and hsa-miR-381-3p. We selected candidate valuables which have significantly 
correlated with mean PPD in Pearson’s correlation analysis (p < 0.05). The final model was constructed 
based on the maximum adjusted R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), 
the R-squared was 0.212, and the adjusted R-squared was 0.191. N: number. CI: confidence interval. 
B: unstandardized regression coefficient. β: standardized coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t = A age Ct (miRNA) − Average
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group, as compared with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-
5p) was down-regulated (f ld change < 0.5) in the sev re periodontitis group, as compared with the 
no/mild periodontitis grou . From these data, hsa-miR- 81-3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa miR-30b-5p were selected for further an lys s. 
Table 2. List of the differentially expressed miRNAs between severe and no/mild periodontitis (Fold 
Chang  >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
Fold Change p Value 
N / il   No/Mild Severe no/Mild Severe 
hsa-miR-381-3p 34 88 33.05 2.35 0.49 0.20 0.71 3.63 0.01 
hsa-miR-543 34 89 33.48 2.36 0.92 0.20 0.53 2.70 0.12 
hsa-miR-144-3p 33 92 32. 4 1.39 0.28 0.38 0.82 2.16 0.51 
hsa-miR-30b-5p 30 05 31. 2 −2.48 −1.24 5.57 2.36 0.42 0.14 
housekeeping small RNA 32.53 32.56       
Fold-change v lues great r than one indicate up-regulation and less than one indicate down-regulation. 
Average ⊿Ct = Average Ct (miRNA) − Aver ge ⊿Ct (housekeeping small RNA). Fold change = 2^ 
(- e⊿Ct (severe))/2^ (-Average⊿Ct (no/mild)). Average Ct values of housekeeping small 
RNAs mean average Ct of SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value 
was calculated by the Stude t’s t-test. 
2.3. Evaluating Validation of S lected miRNAs 
We selected hsa-miR 81-3p, 543, hsa-miR-144-3p, and hsa-miR-30b-5p and perfor ed 
the qua titative real-time PCR assays by inventorie  TaqMan miRNA assays (Applied Biosyst m , 
Fos er City, CA, USA) for all participa ts (Figure S2). There were no significant differences in miRNAs 
expression among three g oups. Next, we evaluat d the r lationships between the relative 
expressions of the miRNAs and clinical parameters (mean PPD, mean CAL, BOP, and Plaque control 
record) by Pearson’s correlation t st. There was a significant positive mild correlation between the 
relative expression of hsa-miR-381-3p and mean PPD (r = 0.181, p = 0.047) (Figure 1). In addition, we 
examined the relationship between hsa-miR-381-3p and mean PPD by the stepwise method of 
multiple linear regression analysis. It was also shown that the relative expression of hsa-miR-381-3p 
was significantly correlate  with mean PPD (p = 0.049) (Table 3) by the multipl  linear regr ssi n 
analysis. For the other miRNAs, th re was no sig ificant correlation betwe n t e rel tive expressions 
of th  miRNAs and the clinical parameters. 
Table 3. Multiple line r regression a alysis with mean PPD as the dependent variable (N = 120). 
Variables B (95%CI) β p Value VIF 
Intercept 1.917 (1.760, 2.073) - <0.001 - 
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1.036 
Gender −0.148 (−0.279, −0.017) −0.187 0.027 1.036 
hsa-miR-381-3p 0.054 (0.010, 0. 23) 0.166 0.049 1.022 
The c ndidate variables for the model were age, gender, BOP (%), Plaque control record (%), number 
of t eth pr sent, an  hsa-miR-381-3p. We sel cted candidate valuables which have significantly 
l ted with mean PPD in Pearso ’s correlation analysis (p < 0.05). The final model was constructed 
based on the maximum adjusted R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), 
the R-squared as 0.212, and the adjusted R-squared was 0.191. N: number. CI: confidence interval. 
B: unstandardized regress o  coefficient. β: standardized coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t (hous keeping sm ll RNA). Fold change = 2ˆ (-Average
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group, s compared with the no/mild periodontitis group (Table 2, Figure S1). One miRNA (hsa-30b-
5p) was d wn-regulated (fold chang  < 0.5) in the severe periodontitis group, as compared with the 
no/mild periodontitis group. From these data, hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa-miR-30b-5p were selected for further analysis. 
Table 2. List of the differentially expresse miRNAs between severe and no/mild periodontitis (Fold 
Change >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
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RNAs mean average Ct of SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value 
was cal ulat d by the Student’s t-te t. 
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We selecte 81 3 , hsa-miR-543, hsa-miR-144-3p, and hsa-miR-30b-5p and performed 
the quan itative real-tim  PCR ass ys y inve toried TaqMan miRNA assays (Applied Biosystems, 
Foster City, CA, USA) for all participants (Figure S2). There were no significant differences in miRNAs 
expression among three groups. N xt, we evaluated the relationships between the relative 
expr ssions of the miRNAs and clinical parameters (mean PPD, mean CAL, BOP, and Plaque control 
record) by P arson’s correlation test. There was a significant positive mild correlation between the 
relative expr ssion of hsa-miR-381-3p and mean PPD (r = 0.181, p = 0.047) (Figure 1). In addition, we 
examined the relations ip b t een hsa-miR-381-3p and mean PPD by the stepwise method of 
multiple lin r regression analysis. It was also shown that the relative expression of hsa-miR-381-3p 
wa  signif cantl  corr lated with me n PPD (p = 0.049) (Ta le 3) by the multiple linear regression 
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The candidate variables for the model were age, gender, BOP (%), Plaque control record (%), number 
of te th present, and hsa-miR-381-3p. We selected candidate valuables which have significantly 
orrelated with mean PPD in Pearson’s orrelation analysis (p < 0.05). The final model was constructed 
based on the m ximum adjusted R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), 
the R-squared was 0.212, an  the adjusted R-squared was 0.191. N: number. CI: confidence interval. 
B: unstandardized regressio  coefficient. β: standardized coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t
(severe))/2ˆ (-Average
Molecules 2019, 24, x FOR PEER REVIEW  3 of 11 
 
group, as compared ith the o/mild p riodontitis group (T ble 2, Figur  S1). O  miRNA (hsa-30b-
5p) was down-regulat  (fold chan e < 0.5) in the severe period ntitis group, s compared with the 
no/mi d peri dontitis group. From these data, hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and 
hsa-miR-30b-5p were selected for further analysis. 
Table 2. List o  the differentially xpressed iR s betw n severe and no/mild periodontitis (Fold 
Change >2 or < 0.5). 
miRNAs 
Average Ct Average ⊿Ct Average 2^-⊿Ct 
Fold Change p Value 
No/Mild Severe No/Mild Severe no/Mild Severe 
hsa-miR-381-3p 34.88 33.05 2.35 0.49 0.20 0.71 3.63 0.01 
hsa-miR-543 34.89 33.48 2.36 0.92 0.20 0.53 2.70 0.12 
hsa-miR-144-3p 33.92 32.84 1.39 0.28 0.38 0.82 2.16 0.51 
hsa-miR-30b-5p 30.05 31.32 −2.48 −1.24 5.57 2.36 0.42 0.14 
housekeeping small RNA 32.53 32.56       
Fold-change values gr ater than one indicat u -regulation and less than one indicate down-regulation. 
Average ⊿Ct = Average Ct (miRNA) − Average ⊿Ct (h usekeeping small RNA). Fold change = 2^ 
(-Averag ⊿Ct (severe))/2^ (-A er e⊿Ct (no/mild)). Average Ct values of hous keeping small 
RNAs mean average Ct of SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value 
was calculated by the Student’s t-test. 
2.3. Evaluating Validation of Selected miRNAs 
We selected a-miR-381-3p, hsa-miR-543, h -miR-144-3p, and a-miR-30b-5p and performed 
the quantitative real-time PCR assays by inventoried T qMan miRNA ass ys ( pplied Biosystems, 
Foster City, CA, USA) for all participants (Figur  S2). Th re were no significant d ff rences in miRNAs 
expression amo g three groups. Next, we valuated the r lationships between the relative 
expressions of he miRNAs and cl ical parameters ( ean PPD, mea  CAL, BOP, and Plaque ntr l 
record) by Pearson’s correl tion test. There was a significant positiv  mild correlati  between the 
relative expressio  of hsa-miR-381-3p and mean PD (r = 0.181,  = 0.047) (Figure 1). In addi ion, we 
exami ed the relationship betw en hsa-miR-381-3p and mean PPD by  stepwis  m thod f 
multipl  linear regres io  an lysis. It was also shown that the relative expres ion of hsa-miR-381-3p 
was significantly correlated with mean PPD (p = 0.049) (Tabl  3) by the multiple lin ar gression 
analysis. For the ther i s, there was o significant correlation betw en the relative expressions 
of the miRNAs and the clinical parameters. 
Table 3. Multiple linear regression analysis with mean PPD as the dependent variable (N = 120). 
Variables B (95%CI) β p Value VIF 
Intercept 1.917 (1.760, 2.073) - <0.001 - 
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1.036 
Gender −0.148 (− .279, −0.017) − .187 0.027 1.036 
hsa-miR-381-3p 0.054 (0.010, 0.123) 0.166 0.049 1.022 
The c ndidate variables for th  model wer ge, gender, BOP (%), Plaque control record (%), number 
of teeth present, and hsa-miR-381-3p. We selected candidate v lu bles which have significantly 
correlated with me n PPD in Pear on’s correlation an lys s (p < 0. 5). Th  final mo el was constructed 
based on the maximum adj st  R-squared an  VIF less than 10. The F-sta is ic wa 10.392 (p < 0.00 ), 
the R-squared was 0 212,  the adjusted R-squar d was 0.191. N: numb r. CI: confi ence interv l. 
B: unstandardized re ression coeffici nt. β: standardiz  coefficient. VIF: variance inflation factor. 
PPD: probing pocket depth. BOP: bleeding on probing. 
t (no/mild)). Aver g Ct values of housekeeping small RNAs m an average Ct of
SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p. The p value was calculated by the Student’s t-test.
2.3. Evaluating Validation of Selected miRNAs
We selected hsa-miR-381-3p, hsa-miR-543, hsa-miR-144-3p, and hsa-miR-30b-5p and performed
the quantitativ rea -time PCR assays by inventoried TaqM n miRNA assays (Applied Biosystems,
Foster Ci y, CA, USA) for all participants (Figure S2). There were no si ificant differences i m RNAs
expression among three groups. Next, we ev luated the relationships bet een the relative expressions
of the miRNA and clinical pa ameters (mean , e , BOP, and Plaque control record)
by Pearson’s correlation t st. There was a signific nt p sitive mild correlation betw en the relative
expression of hsa- iR-381- e (r . , . ) ( igure 1). In addition, we examin d
the relationship betw en hs -miR-381-3p and mean PPD by the stepwise method of ltiple linear
regression analysis. It was als show t at the rel tive xpression of hsa-miR-381-3p was significantly
correlated wi h mea PPD (p = 0.049) (Table 3) by th multiple line r regression analysi . For the other
miRNAs, there was no significant c rrela ion between the relativ expr ssions of t e i NAs a d th
clinical p rameters.
Table 3. Multiple linear regression analysis with mean PPD as the dependent variable (N = 120).
Variables B (95%CI) β p Value VIF
Intercept 1.917 (1.760, 2.073) - <0.001 -
BOP 0.014 (0.008, 0.021) 0.353 <0.001 1. 36
Gender −0.148 (−0.279, −0.017) −0.187 0.027 1.036
hsa-miR-381-3p 0.054 (0.010, 0.123) 0.166 0.049 1.022
The candidate variables for the model were age, gender, BOP (%), Plaque control record (%), number of teeth
present, and hsa-miR-381-3p. We selected candidate valuables which have significantly correlated with mean PPD
in Pearson’s correlation analys s (p < 0.05). The fi l model was constructed based on the maximum adjusted
R-squared and VIF less than 10. The F-statistic was 10.392 (p < 0.001), the R-squared was 0.212, and the adjusted
R-squared was 0.191. N: number. CI: confidence interval. B: unstandardized regression coefficient. β: standardized
coefficient. VIF: variance inflation factor. PPD: probing pocket depth. BOP: bleeding on probing.
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2.4. Bioinformatics
With regard to hsa-miR-381-3p, the target genes were strongly associated with pathways for cancer,
focal adhesion, Wnt signaling, and MAPK (mitogen-activated protein kinase) signaling (Table 4).
Table 4. Pathway analysis of target genes for hsa-miR-381-3p.
Pathway Target Genes p-Value
Pathways in cancer
DVL2, PTCH1, SOS1, EGLN3, MET, LEF1, MAPK1, STAT1, KITLG,
PIAS2, DCC, FGF1, FZD6, KIT, FOXO1, PRKCB, GLI3, NRAS, NFKBIA,
SMAD2, BIRC3, AKT3, BRAF, MAPK10, PRKCA, CRK, LAMC1, MAPK8,
COL4A1, TRAF6, FZD4, VHL, MITF, ITGAV, WNT5A, RAC1, FZD3,
PTK2, FGF7, PIK3CG, TP53, VEGFA, HSP90AB1, FGF12, HDAC2, CBLB,
PTGS2, FGFR2
1.02× 10−12
Focal adhesion
SOS1, MET, MAPK1, PDGFC, TLN2, ITGA4, PRKCB, ACTG1, ROCK2,
PDGFD, CCND2, MYL12B, BIRC3, AKT3, ITGA8, RAF, PARVA,
MAPK10, PRKCA, CRK, LAMC1, MAPK8, COL4A1, MYLK3, ITGAV,
RAC1, PTK2, FYN, PIK3CG, ITGB8, VEGFA, COL11A1
1.48 × 10−9
Wnt signaling
pathway
DVL2, SIAH1, LEF1, MAP3K7, FZD6, PRKCB, ROCK2, CCND2,
PPP2R5A, SMAD2, CXXC4, MAPK10, PRKCA, PPP2R5E, MAPK8,
SFRP2, L P6, FZD4, PRKACG, WNT5A, NFATC2, RAC1, FZD3, NFAT5,
CAMK2G, TP53, PRKACB
2.90 × 10−9
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Table 4. Cont.
Pathway Target Genes p-Value
MAPK signaling
pathway
NTRK2, CACNA2D1, SOS1, MAPK1, MAP3K7, FGF1, CACNA1C,
CACNA1E, PRKCB, IL1R1, NRAS, DDIT3, AKT3, BRAF, ELK4, MAPK10,
TAOK1, PRKCA, CRK, MAPK8, TRAF6, PRKACG, MAPK14, RRAS2,
NFATC2, RAC1, FGF7, RPS6KA3, ARRB1, TP53, FGF12, CACNB2,
PRKACB, FGFR2
6.83 × 10−8
Regulation of actin
cytoskeleton
ARHGEF7, SOS1, MAPK1, FGF1, PDGFC, ITGA4, ACTG1, ROCK2,
PDGFD, NRAS, SSH2, MYH10, CFL2, MYL12B, NCKAP1, ITGA8, MYH9,
BRAF, GNA13, CRK, MYLK3, ITGAV, RRAS2, RAC1, PTK2, FGF7,
PIK3CG, ITGB8, FGF12, FGFR2
6.94 × 10−8
Insulin signaling
pathway
SOS1, MAPK1, EIF4E, FOXO1, NRAS, PRKAR2B, RPS6KB1, AKT3,
BRAF, PRKAR2A, SOCS4, MAPK10, CRK, MAPK8, PRKACG, PRKAG3,
RHOQ, PRKAA2, PIK3CG, SORBS1, PHKG2, PRKACB, CBLB
1.01 × 10−7
Ubiquitin mediated
proteolysis
ANAPC10, UBE2C, SIAH1, HERC3, PIAS2, UBR5, CUL4B, CDC23,
HERC4, ITCH, ANAPC13, UBE3A, BIRC3, UBE2W, UBE2G1, TRIM32,
NEDD4, MID1, TRAF6, SYVN1, VHL, UBE2E2, CBLB
1.17 × 10−7
ErbB signaling
pathway
SOS1, MAPK1, PRKCB, NRAS, ABL2, RPS6KB1, NCK1, AKT3, BRAF,
HBEGF, MAPK10, PRKCA, CRK, MAPK8, PTK2, CAMK2G, PIK3CG,
CBLB
1.86 × 10−7
Long-term
potentiation
MAPK1, CAMK4, CACNA1C, PRKCB, NRAS, GRM5, BRAF, PRKCA,
GRM1, ITPR2, GNAQ, PRKACG, GRIN2A, RPS6KA3, CAMK2G,
PRKACB
1.97 × 10−7
Axon guidance
SEMA3C, CXCR4, MET, MAPK1, DCC, ROCK2, NRAS, CFL2, ABLIM3,
NCK1, NTN4, ABLIM1, NFATC2, RAC1, PTK2, NFAT5, UNC5D, FYN,
EFNB2, EPHA3, SRGAP2
6.88 × 10−7
Multiple bioinformatics databases including TargetScan, miRanda, and miRWalk were used. Predicted targets
were included in three databases. We used Genecodis 3.0 to predict related signaling pathways of these predicted
target genes.
3. Discussion
In this study, we hypothesized that miRNAs reflecting periodontal condition exist in saliva.
In PCR array analysis, we selected hsa-miR-381-3p as a biomarker of periodontitis severity. In addition,
we confirmed that relative expression of hsa-miR-381-3p was correlated with mean PPD by multiple
linear regression analysis. The results indicate that salivary hsa-miR-381-3p may reflect periodontal
condition in chronic periodontitis patients. This is consistent with previous results, revealing that
the miR-381 in blood samples was one of the most significantly related miRNAs with chronic
periodontitis [22]. However, the effect sizes (Pearson’s correlation coefficients, 0.071–0.181) were
small. It is possible that biological factors which we could not evaluate in this study may affect clinical
parameters and obscure the correlation with hsa-miR-381-3p.
There is little research carried out on the potential role of miR-381 in the innate immune response.
However, a previous study found that treatment with LPS (lipopolysaccharide) elevated miR-381
expression in A549 cells (immortalized cells derived from human adenocarcinomas’ alveolar basal
epithelial cells isolated from the lungs) in a time- and dose-dependent manner [23]. LPS is one
of bacterial pathogens and immune responses to LPS play a crucial role in the pathogenesis of
periodontitis [24]. In this study, there was no statistical correlation between hsa-miR-381-3p and
plaque control records, suggesting that the expression of hsa-miR-381-3p did not directly reflect
supragingival bacterial pathogens. On the other hand, the up-regulated expression of hsa-miR-381-3p
in our observations may be associated with the increased immune responses to subgingival bacterial
pathogens such as LPS. In addition, LPS is related to interferons in innate immune response,
and there is a correlation between interferon-gamma in the crevicular fluid and periodontitis [25].
Interferon-gamma may correlate with the expression of hsa-miR-381-3p. Therefore, we need to carry
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out further study in the future about the relationship between miRNA expression and subgingival
periodontopathic bacteria in immune response.
Studies have shown the relationship between periodontitis and miRNA profiles in periodontal
tissue. For example, with regard to miR-181b, miR-19b, miR-23a, miR-30a, miR-let7a and miR-301a,
miRNAs levels in periodontal tissue of chronic periodontitis patients are higher than those of
healthy controls [26]. Another study reported that hsa-miR-150, hsa-miR-223 and hsa-miR-200b were
overexpressed and hsa-miR-379, hsa-miR-199a-5p and hsa-miR-214 were underexpressed in inflamed
gingival tissues [27]. Furthermore, it has been demonstrated that gingival tissue levels of miR-146a
are correlated with periodontal parameters [28]. These observations show that periodontitis is able
to modulate the expression of miRNAs in the periodontal tissue. In the present study, we found
that salivary expression of hsa-miR-381-3p is correlated with PPD in chronic periodontitis patients.
Periodontitis may up-regulate the expression of hsa-miR-381-3p in periodontal tissue, and such a
condition would contribute to an increase of hsa-miR-381-3p in saliva. However, in the present
study, relative expression of hsa-miR-381-3p was correlated with mean PPD, but not with mean CAL.
This indicates that hsa-miR-381-3p reflected periodontal status rather than the present periodontal
disease. Because the expression of hsa-miR-381-3p was correlated with only periodontal status, it is
possible that the changes in hsa-miR-381-3p expression was not found from the periodontal disease
tissues in the other studies [19,27]. In addition, hsa-miR-381-3p might be derived not only from
gingival tissues directly, but also from other tissues affected by periodontitis. Further studies are
needed to clarify if this is the case.
Bioinformatics analysis showed that the target genes of hsa-miR-381-3p correlated with MAPK
signaling pathway. MAPK signaling is closely related to the pathology of periodontitis [29]. Therefore,
it is possible that the modulated expression of hsa-miR-381-3p in saliva has an influence on periodontal
condition through the MAPK signaling pathway. The expression of hsa-miR-381-3p in saliva not only
reflects periodontal condition, but may also affect the periodontal tissue. However, because this study
was cross-sectional, further studies are needed to clarify this point.
A clinical study demonstrated that saliva could be a feasible diagnostics tool of tongue squamous
cell carcinoma and that miR-139-5p could be a potential biomarker of early tongue squamous cell
carcinoma detection [30]. The other study also revealed that miR-4484 was significantly upregulated
in the salivary exosomes of patients with oral lichen planus [31]. Furthermore, in the present study,
there was a positive correlation between hsa-miR-381-3p and periodontal condition. The previous and
present results support the notion that salivary miRNAs are novel biomarkers for oral diseases.
In general, periodontal condition was evaluated using X-ray images, and clinical parameters such
as PPD, CAL, mobility and BOP. However, because these methods need some experiences and physical
burden or pain for periodontitis patients, diagnosis by a dentist is necessary. On the other hand, saliva
is one of the least invasive and easiest body fluids to collect. Therefore, anyone can perform salivary
tests. Periodontitis often progresses without subjective symptoms. It may therefore contribute to the
screening of periodontitis progression if we establish a system that can indicate severe periodontitis by
saliva test at home.
There are some limitations in this study. First, in PCR array analysis, we analyzed 84 miRNAs
expressions related to the inflammatory response and autoimmunity. However, it is possible that
other miRNAs are associated with periodontitis. Second, external validity is limited because all of
the patients were recruited from Okayama University Hospital. Third, we used PCR array to select
candidate miRNAs reflecting periodontitis. However, because the human genome may encode over
1000 miRNAs, next generation sequencing is recommended to investigate the whole transcriptome.
Fourth, this was a cross-sectional pilot study. It is necessary to improve the reliability of this study by
researching the longitudinal relationship between hsa-miR-381-3p and periodontal condition.
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4. Materials and Methods
4.1. Experimental Design and Participants’ Recruitment
This study was carried out according to the Declaration of Helsinki (World Medical Association,
2002) and was admitted by the Ethics Committee of Okayama University Hospital (approval
number: 1603-002). This study was designed as multiphase study (screening phase and selection
phase, validation phase, and bioinformatics phase) to identify salivary miRNAs as biomarkers of
periodontitis (Figure 2). In the screening phase and the selection phase (a pilot study), a comparison
of salivary miRNAs profiles with no and mild (no/mild) and severe periodontitis patients was done
to select candidate miRNAs reflecting periodontitis. In the next two phases (a cross-sectional study),
the validation of selected salivary miRNAs in a pilot study was confirmed using the individual samples.
After obtaining written informed consent, we recruited 120 patients (median age, 68.4 years) for
participants from the Department of Preventive Dentistry, Okayama University Hospital. Participant
recruitment was carried out from July 2016 to October 2016. This sample size was based on the number
of patients that we were able to recruit during a 4-month period. All participants had been diagnosed
with chronic periodontitis [32], and they did not have oral pain, oral disorders or dental treatments
other than supportive periodontal therapy. Exclusion criteria were as follows; pregnancy, less than
40 years of age, use of anti-inflammatory drug, or the onset of acute inflammation of periodontal tissue
within the 3-month period before the oral examinations.
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4.2. Oral Examination
PPD, CAL and BOP were examined. Measurement points of PPD and CAL were six sites
on all teeth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual and disto-lingual).
We measured PPD and CAL using a dental probe (Hu-Friedy, Chicago, IL, USA). Bleeding sites
on probing (25 g probing force) were counted and the percentage of bleeding sites was calculated.
Plaque was stained with erythrosine. At four sites (mesial, distal, buccal and lingual) around each
tooth, we recorded sites where plaque was present and calculated percentage of plaque presence
sites [33]. Six trained and calibrated dentists (T. T., D. E., T. A., T. M., H. M. and T. Y.) carried out all
clinical procedures. The non-parametric kappa test and intra-class correlation was used for the data
analysis. The k coefficients for intra- and inter-examiner and intra-class correlation coefficients were
>0.8. After oral examination, we classified periodontitis severity (no/mild periodontitis, moderate
periodontitis, or severe periodontitis) with accordance to the joint Center for Disease Control/American
Association of Periodontology working group [1]. This section is not mandatory, but can be added to
the manuscript if the discussion is unusually long or complex.
4.3. Questionnaire
Participants answered a questionnaire. Questionnaire items covered smoking status, body mass
index (BMI) (weight in kilograms per square of height in meters), presence of diabetes mellitus,
and frequency of tooth brushing per day.
4.4. Saliva Collection and RNA Extraction
Unstimulated whole saliva (1–2 mL) was collected as reported previously [34]. Saliva was collected
from 7:00 AM to 12:00 on the same day as oral examination. In this study, any inhibitors or preservatives
were not added to the saliva. After saliva was collected, we removed cells and debris in saliva by
centrifugation (10 min, 2000 g, room temperature). Supernatant was isolated and stored at 4 ◦C for
up to 6 h, then it was stored at −80 ◦C until it was used. We used total exosome isolation reagent
(Invitrogen, Carlsbad, CA, USA) to extract Exosome in saliva samples (300 µL). A total exosome
RNA and protein isolation kits (Invitrogen, Carlsbad, CA, USA) [34] were used to isolate total RNA,
containing miRNAs from salivary exosome samples. Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA) was used to confirm quality of total RNA, which contained <500 nucleotides
and no/little 18S and 28S ribosomal RNA.
4.5. Selection of Candidate miRNAs Reflecting Periodontitis
In the screening phase, PCR array analysis was performed in triplicate. The severe periodontitis
patients and the no/mild periodontitis patients were divided into three subgroups respectively
(no/mild 1 [N = 9], no/mild 2 [N = 9], no/mild 3 [N = 8], severe 1 [N = 12], severe 2 [N = 12],
and severe 3 [N = 12]). The Inflammatory Response and Autoimmunity miScript miRNAs PCR Array
(SA Biosciences, Frederick, MD) was conducted. This array had 84 miRNA assays, which includes
candidate housekeeping small RNA (SNORD61, SNORD68, SNORD95, SNORD96A and RNU6-6p).
Reverse transcription was conducted using the miScript II RT kit (QIAGEN, Hilden, Germany)
for reverse transcription. The data was analyzed using an online analysis tool (SA Biosciences;
http://pcrdataanalysis.sabiosciences.com/mirna). We used the 2−∆∆Ct method to analyze the relative
quantification of miRNAs [35]. In addition, we made a heat map to visualize the results of one-way
hierarchical clustering of miRNAs in the six subgroups (SA Biosciences; http://pcrdataanalysis.
sabiosciences.com/mirna) from the Ct values of the array. In the selection phase, we selected candidate
miRNAs that showed statistically significant (p < 0.05) fold changes (<0.5 or >2).
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4.6. Evaluating Validation of Selected miRNAs
In the validation phase, reverse transcription polymerase chain reaction (RT-PCR) analysis on
individual samples (N = 120) was conducted. TaqMan microRNA Assays (Life Technologies (Thermo
Fisher Scientific, Carlsbad, CA, USA) and the Mx3000P Real-time QPCR System (Agilent Technologies,
Santa Clara, CA, USA) were used [36,37]. The thermal cycler was set at 50 cycles. We included data
with a threshold cycle (Ct) value of <50 in each analysis. The relative expression rates of each miRNA
were calculated using the 2−∆∆Ct method [35]. Internal control miRNA was U6 snRNA (Figure S3).
We normalized the relative expression of candidate miRNA by log10 transformation for analysis.
4.7. Bioinformatics
In the bioinformatics phase, we predicted target genes of candidate miRNAs using miRWalk [38].
We used TargetScan, miRanda, and miRWalk for multiple bioinformatics analysis in miRWalk.
We included at least two databases to predict target genes. We predicted related signaling pathways of
these predicted target genes using genedodis 3.0 [39–41].
4.8. Statistical Analysis
SPSS statistics version 22.0 (IBM Japan, Tokyo, Japan) was used for statistical analysis. We used a
Student’s t-test to compare the no/mild periodontitis group with the severe periodontitis group for
PCR array. The data are presented as mean values± standard deviation (SD). The differences in miRNA
expressions among three groups were analyzed by one-way ANOVA followed by the Tukey’s method.
A Pearson’s correlation test was carried out to analyze the relationships between candidate miRNAs
and clinical parameters (mean PPD, mean CAL, BOP, and Plaque control record). We also examined
the relationship between candidate miRNAs and significantly correlated variables by the stepwise
method of multiple linear regression analysis. We considered p < 0.05 as significant differences.
5. Conclusions
The relative expression of salivary hsa-381-3p was correlated with periodontal condition in
chronic periodontitis patients within the limitation. Measuring salivary hsa-381-3p may be a useful
new biomarker for periodontitis.
Supplementary Materials: The following are available online, Figure S1: Scatterplot of the results of miRNA PCR
array analysis, Figure S2: Relative expressions of miRNAs (A: hsa-miR-381-3p, B: hsa-miR-543, C: hsa-miR-144-3p,
and D: hsa-miR-30b-5p) among three groups using quantitative real-time PCR assays, Figure S3: Ct values of U6.
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